125 related articles for article (PubMed ID: 37126399)
1. Comparison of Hematocrit Change in Testosterone-deficient Men Treated With Intranasal Testosterone Gel vs Intramuscular Testosterone Cypionate: A Randomized Clinical Trial.
Rivero MJ; Ory J; Diaz P; Thirumavalavan N; Han S; Reis IM; Ramasamy R
J Urol; 2023 Jul; 210(1):162-170. PubMed ID: 37126399
[TBL] [Abstract][Full Text] [Related]
2. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
Zitzmann M; Cremers JF; Krallmann C; Kliesch S
Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
[TBL] [Abstract][Full Text] [Related]
3. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels.
Kenny AM; Prestwood KM; Raisz LG
Endocr Res; 2000 May; 26(2):153-68. PubMed ID: 10921445
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate.
Choi EJ; Xu P; Barham D; El-Khatib FM; Yafi FA; Kavoussi PK
J Urol; 2022 Mar; 207(3):677-683. PubMed ID: 34694927
[TBL] [Abstract][Full Text] [Related]
5. Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men.
Maggi M; Heiselman D; Knorr J; Iyengar S; Paduch DA; Donatucci CF
J Sex Med; 2016 Aug; 13(8):1220-6. PubMed ID: 27436077
[TBL] [Abstract][Full Text] [Related]
6. Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100 mg IM weekly or 200 mg IM biweekly.
El-Khatib FM; Huynh LM; Kopelevich A; Osman MM; Choi E; Nguyen JT; Dianatnejad S; Wu Q; Olivas MG; Spitz A; Lowry J; Losso BY; Khera M; Angulo-Llanos L; Patel P; Ramasamy R; Yafi FA
Int J Impot Res; 2022 Sep; 34(6):558-563. PubMed ID: 34257404
[TBL] [Abstract][Full Text] [Related]
7. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.
Leder BZ; Rohrer JL; Rubin SD; Gallo J; Longcope C
J Clin Endocrinol Metab; 2004 Mar; 89(3):1174-80. PubMed ID: 15001605
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Intratesticular Testosterone between Men Receiving Nasal, Intramuscular, and Subcutaneous Pellet Testosterone Therapy: Evaluation of Data from Two Single-Center Randomized Clinical Trials.
Diaz P; Reddy R; Blachman-Braun R; Zucker I; Dullea A; Gonzalez DC; Kresch E; Ramasamy R
World J Mens Health; 2023 Apr; 41(2):390-395. PubMed ID: 35791295
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA
J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
[TBL] [Abstract][Full Text] [Related]
11. A cross-sectional comparison of secondary polycythemia in testosterone-deficient men treated with nasal testosterone gel vs. intramuscular testosterone cypionate.
Best JC; Gonzalez D; Masterson TA; Blachman-Braun R; Pai R; Ramasamy R
Can Urol Assoc J; 2021 Feb; 15(2):E118-E122. PubMed ID: 32744998
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
[TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.
Sih R; Morley JE; Kaiser FE; Perry HM; Patrick P; Ross C
J Clin Endocrinol Metab; 1997 Jun; 82(6):1661-7. PubMed ID: 9177359
[TBL] [Abstract][Full Text] [Related]
14. Comparing Rates of Polycythemia in Hypogonadal Men Using Nasal Testosterone Gel Versus Intramuscular Testosterone: Update of a Randomized Clinical Trial.
Ory J; Diaz P; Rivero MJ; Clavijo RI; Thirumavalavan N; Blachman-Braun R; Loloi J; Bernstein A; Ramasamy R
Eur Urol Focus; 2023 Jan; 9(1):14-16. PubMed ID: 36109330
[TBL] [Abstract][Full Text] [Related]
15. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
Morgentaler A; Benesh JA; Denes BS; Kan-Dobrosky N; Harb D; Miller MG
J Sex Med; 2014 Nov; 11(11):2818-25. PubMed ID: 25131184
[TBL] [Abstract][Full Text] [Related]
17. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone.
Shabsigh R; Kaufman JM; Steidle C; Padma-Nathan H
J Urol; 2004 Aug; 172(2):658-63. PubMed ID: 15247755
[TBL] [Abstract][Full Text] [Related]
18. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression).
Shores MM; Kivlahan DR; Sadak TI; Li EJ; Matsumoto AM
J Clin Psychiatry; 2009 Jul; 70(7):1009-16. PubMed ID: 19653976
[TBL] [Abstract][Full Text] [Related]
20. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).
Buvat J; Montorsi F; Maggi M; Porst H; Kaipia A; Colson MH; Cuzin B; Moncada I; Martin-Morales A; Yassin A; Meuleman E; Eardley I; Dean JD; Shabsigh R
J Sex Med; 2011 Jan; 8(1):284-93. PubMed ID: 20704642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
